Results 11 to 20 of about 12,163 (174)
Population pharmacokinetics and pharmacodynamics of edoxaban in pediatric patients
CPT: Pharmacometrics & Systems PharmacologyEdoxaban is an orally active inhibitor of activated factor X (FXa). Population pharmacokinetic (PK) and pharmacodynamic (PD) analyses were performed to characterize the PK and PK–PD relationships of edoxaban in pediatric patients to identify the ...
Peng Zou +4 more
doaj +2 more sources
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada +2 more
openaire +3 more sources
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. [PDF]
, 2021 BACKGROUND The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied.
Rodés-Cabau, Josep +40 more
core +3 more sources
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
Frontiers in Pharmacology, 2021 Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin +8 more
doaj +1 more source
Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY
Thrombosis Update, 2021 Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation.
Jan Beyer-Westendorf +5 more
doaj +1 more source
Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats
TH Open, 2021 Coagulation–fibrinolytic system activity shows daily rhythmicity, with hypercoagulability in the morning and hypocoagulability in the evening. Consequently, the efficacy of anticoagulants may be influenced by their dosing time.
Naoto Nagata +3 more
doaj +1 more source
Thrombosis Journal, 2020 Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima +5 more
doaj +1 more source
Neurological Research and Practice, 2021 Background Direct oral anticoagulants (DOAC) including edoxaban are increasingly used for stroke prevention in atrial fibrillation. Despite treatment, annual stroke rate in these patients remains 1–2%.
Florian Härtig +13 more
doaj +1 more source
Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study
Brain Sciences, 2023 Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings.
Irene Scala +10 more
doaj +1 more source